top of page
Focus

Therapeutic Focus

CLINICAL SUMMARY
Validating the Potential of abenacianine for injection (VGT-309) in Solid Tumors

In Phase 1 and 2 clinical studies, abenacianine for injection was shown to be safe and well- tolerated at all doses studied. Other important clinical highlights included:

 

  • abenacianine for injection imaging identified visually non-discernable, non-palpable tumors in real time.
     

  • abenacianine for injection visualization showed an unexpected positive lymph node that the surgeon removed and subsequently confirmed as containing malignancy.
     

  • abenacianine for injection tumor visualization allowed for preservation of healthy tissue following prior lung cancer surgery.
     

  • abenacianine for injection imaging identified a colorectal cancer tumor that had metastasized to a patient’s lung, was not visible on PET and CT imaging, and the surgeon would have otherwise missed.

Phase 1 and and 2 Clinical Studies Have Yielded Compelling Data

Results suggest abenacianine for injection is safe and well-tolerated, and labels human lung tumors during resection surgeries.

 

Phase 2 multi-center safety and efficacy study for cancer in the lung (NCT06145048)

 

Phase 2 clinical study in lung cancer surgery ongoing (NCT05400226)

Phase 2 dose-ranging study in lung cancer surgery ongoing (ACTRN12621000301864)


Phase 1 clinical study for safety in healthy human volunteers completed (ACTRN12620000948998)

1

1. Scientific manuscript in preparation

bottom of page